Beth Israel Deaconess Medical Center, Inc.

The Beth Israel Hospital Association

Arcturus Pharmaceutical Corporation

Stephen J Galli

Richard J Sharpe

Kenneth A Arndt

Raj Kumar Razdan

Peter C Meltzer

Howard Paul Sard

See-Ying Tam

Kenenth A Arndt

Maureen H McAloon

Mindy Tsai

Novel gene, rin2, and encoded protein are disclosed which can inhibit the functional response induced by Ras-dependent signaling pathways are disclosed. Methods of inhibiting or enhancing Ras-dependent signaling and methods of treatment utilizing Rin2 are also disclosed.

Rin2, a novel inhibitor of Ras-mediated signaling

A method for the treatment of a cutaneous, ocular, or mucosal pathological condition which is associated with immune response in a human or other mammal, that includes topical application of an effective amount of spiperone or a spiperone derivative or its pharmaceutically acceptable salt, in a pharmaceutically-acceptable diluent or carrier for topical application.

Topical application of spiperone or derivatives thereof for treatment of

Use of spiperone or spiperone derivatives as immunosuppressant agents

A method for the topical or systemic treatment of disorders mediated by proteases which result in skin or mucosal lesions, and in particular, pemphigus, cicatricial pemphigoid, bullous pemphigoid, lichen planus, and canker sores, is disclosed wherein the host is treated with an effective amount of N-acetyl ysteine or a derivative thereof, or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable diluent or carrier for systemic or topical delivery.

Method for treating diseases mediated by proteases

A method for treating atopic dermatitis, hayfever, asthma and pruritis that includes topical or systemic application of an effective amount of buspirone or a buspirone derivative or its pharmaceutically acceptable salt, other than a quaternary salt, optionally in a pharmaceutically-acceptable diluent or carrier.

Topical and systemic application of buspirone or derivatives thereof for

A method for the treatment of a cutaneous, ocular, or mucosal pathological condition which is associated with an immune response in a human or other mammal, that includes topical application of an effective amount of buspirone or a buspirone derivative or its pharmaceutically acceptable salt, optionally in a pharmaceutically-acceptable diluent or carrier for topical application.

Topical application of buspirone for treatment of pathological

A method for suppressing an immune response in a mammal by treating the mammal with an effective amount of spiperone derivative that is without significant neuroleptic effect due to decreased binding to serotonin and/or dopamine receptors as compared with unmodified or uncomplexed spiperone, or due to topical application which maximizes local immunosuppression while limiting systemic absorption and neuroleptic effects. The spiperone derivatives are capable of inhibiting classic contact hypersensitivity reactions.

Growing community of inventors

Winchester, MA, United States of America

Stephen J Galli